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ABSTRACT
Objectives: The aim of the study is to estimate a preference-based single
index for calculating quality-adjusted life years for patients with overac-
tive bladder (OAB), based on a survey of the UK general population using
the 5-dimensional health classiﬁcation system OAB-5D, derived from the
validated Overactive Bladder Questionnaire (OAB-q).
Methods: An interview valuation survey of members of public in the
South Yorkshire, UK was undertaken using the time-trade-off method.
Each respondent was randomly allocated to one of 14 blocks, and valued
seven states each plus the “pits” state, so that a total of 99 states were
valued. A number of multivariate regression models were estimated for
predicting a total of 3125 health state values deﬁned by the classiﬁcation.
Models were compared and selected using a set of criteria, including
overall diagnosis by adjusted R-squared, the sign and signiﬁcance of
individual parameter estimates, the relative size of coefﬁcients within a
given dimension and predictive ability.
Results: The mean model was recommended for use in economic
evaluation.
Conclusion: This will permit the cost-effectiveness of new interventions to
be assessed in patients with OAB using existing and future OAB-q data sets.
Keywords: condition-speciﬁc, health state valuation, OAB-q, TTO.
Introduction
The use of economic evaluation to aid health decision-making,
especially health priority setting and health resources allocation,
has become widespread. Government agencies have been estab-
lished to examine the cost-effectiveness of health-care interven-
tions, such as the National Institute for Health and Clinical
Excellence (NICE) [1] in England and Wales, the Scottish Medi-
cines Consortium [2] for Scotland and similar agencies in Aus-
tralia (Pharmaceutical Beneﬁts Advisory Committee) [3] and
Canada (Canadian Coordinating Ofﬁce for Health Technology
Assessment) [4]. Cost-effectiveness analyzes increasingly use
quality-adjusted life years (QALYs) as the measure of effective-
ness to allow comparisons across different health-care interven-
tions for different medical conditions. The QALY is able to
achieve this by capturing the impact of interventions on the
length of life (in the form of “years”) and/or the quality of life (in
the form of “health state values”) into a single summary
measure, based on people’s preference.
A common way to obtain health state values is to use one of
the “off-the-shelf” generic preference-based instruments, such as
the EQ-5D [5], HUI3 [6], and SF-6D [7]. These instruments
typically consist of two parts: A general health descriptive system
and a ready-to-use scoring algorithm based on public preference.
These measures produce health state values that lie on a scale,
where zero denotes equivalence to being dead and one denotes
equivalence to being in full health. The overall gain from treat-
ment in terms of QALYs is calculated as a function of these
health state values and their associated durations. Owing to their
ease to use and generic nature, which permits comparisons across
different health-care interventions and/or different medical con-
ditions, generic preference-based instruments have been widely
used. Nevertheless, for some medical conditions, the generic
dimensions may be considered to be irrelevant or insensitive in
terms of capturing small but important clinical changes [8].
Overactive bladder (OAB), a syndrome characterized by
urinary urgency with or without urge incontinence, usually with
increased urinary frequency and nocturnal urine [9], is one such
medical condition. Given the symptoms are related to urinary
urgency, frequency, urgency incontinence, and sleep, generic
utility measures such as EQ-5D or SF-6D may not adequately
capture the impact on patient’s health-related quality of life or be
sensitive to change. There is some empiric evidence for this
concern where for example, the SF-36 was found to be unrespon-
sive to improvements after pharmacologic treatment for OAB
[10].
The purpose of this study was to develop an OAB-speciﬁc
preference-based measure with a population value set. To do this,
the methods which have been successfully used to derive the
generic preference-based index SF-6D from the SF-36 [7] were
employed using an OAB-speciﬁc symptom bother and health-
related quality of life instrument, the Overactive Bladder Ques-
tionnaire (OAB-q) [11]. Basically, this methodology consists of
three stages with the ﬁrst stage being to select a subset of OAB-q
items to serve as the dimensions of a trimmed down descriptive
system, and then to decrease the number of severity levels within
each dimension. The ﬁrst stage produces a health state classiﬁ-
cation system, that is not only amenable to being valued using a
preference elicitation technique, but also suffers minimum infor-
mation loss relative to the original instrument. The second stage
is to undertake a survey which asks a representative sample of
the general population to value a selection of states deﬁned by the
reduced classiﬁcation system. The third stage is modeling the
sample health state values and using these models to predict
health state values for all possible states deﬁned by the new
classiﬁcation system. The resulting scoring algorithm or popula-
tion value set will provide a preference-based single index
measure for different OAB-q states and hence for any OAB-q
data sets, contributing toward the calculation of QALYs. The
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ﬁrst stage is brieﬂy summarized in the next section, and reported
elsewhere [12] in more detail, produces a health state classiﬁca-
tion system OAB-5D. This article will provide the details of
the second and the third stage of this three-stage process.
Reducing the OAB-q to Derive a Health
State Classiﬁcation
The OAB-q is a 33-item OAB-speciﬁc questionnaire that consists
of an eight-item Symptom Bother scale and a 25-item Health-
Related Quality of Life scale that has four subscales: coping,
concern, sleep, and social interaction [11]. Responses are based
on a six-point Likert scale. Among continent and incontinent
OAB patients, the OAB-q has demonstrated good internal con-
sistency, reliability, test–retest reliability, concurrent validity, dis-
criminate validity, and responsiveness to treatment-related
change [11,13,14]. The OAB-q has been widely used in patients
with OAB, and for instance a PUBMED search using OAB-q as
the keyword results in 219 articles for years between 1956 and
2007. Nevertheless, the OAB-q cannot be used in cost per QALY
analyzes because the scores are not preference-based.
The number of possible health states that the OAB-q can
distinguish from each other in theory is 633, which is too large for
a valuation survey in practice. Thus, it is necessary to derive a
new classiﬁcation system from the OAB-q which is amenable for
valuation mainly using Rasch analysis [15]. Rasch analysis uses a
logit model to convert ordinal data into a continuous latent scale.
Rasch models were applied to OAB-q data collected from
patients with the aim of selecting a number of items for a reduced
health state classiﬁcation. Five items were chosen to construct a
new health state classiﬁcation system (OAB-5D, see Table 1) and
they are: Urge to urinate, urine loss, sleep impact, coping strat-
egy, and concern with OAB, where each dimension has ﬁve levels
of severity with level 1 denoting no problem and level 5 indicat-
ing an extreme problem. A total of 3125 (= 55) health states can
be deﬁned by the OAB-5D classiﬁcation system, and all OAB-q
data which contain these ﬁve items can be mapped to a speciﬁc
OAB-5D health state (for further details of this article, see the
study by Young et al.) [12].
Methods
Valuation Survey
To elicit preference values for a sample of health states deﬁned by
the OAB-5D, a valuation survey was undertaken. The basic
design of the survey was that selected OAB-5D health states were
valued using the time-trade-off (TTO) technique by a sample of
the general public randomly selected from the electoral register in
South Yorkshire, UK to be representative in terms of age and sex.
General public preferences were sought, because health policy
organizations such as NICE recommend using general public
values.
Given the logistical difﬁculties of valuing all 3125 health
states, a sample of states were selected for direct valuation, using
a balanced design method. In terms of the sample size of health
states needed for this kind of work, researchers have not reached
an agreement. In this study, 98 health states were selected on the
basis of the authors’ previous experience with SF-6D and
resource constraints. Two criteria were used in the selection
process to select those 98 states:
1. Any dimension level has an equal chance of being combined
with all levels of the other dimensions;
2. The resulting health states cover a wide range of the scale
with a mix of good, mild, moderate, and severely ill health
states.
Furthermore, because the modeling process required a larger
number of states to be directly valued than a single respondent
can value in one interview, respondents were divided into 14
subgroups, where each subgroup valued a different subset of
seven health states. To allocate the 98 states to these 14 respon-
dents subgroups, each state was given a severity score, calculated
as the simple sum of the levels across the OAB-5D dimensions,
grouped into seven severity groups (each consisting of 14 states
of similar severity), and then randomly allocated to one of the 14
respondent subgroups. In addition, the worst possible state was
allocated to all 14 respondent subgroups. This way, each respon-
dent valued a set of states balanced in terms of severity, and each
state is valued the same number of times (except for the worst
possible state valued by all respondents).
Specially trained and experienced interviewers conducted
interviews in the respondents’ own home during October 2005.
The interview began with the respondents being asked to
describe their own current state of health, which included com-
pleting the EQ-5D questionnaire and the OAB-5D. This proce-
dure collected information about respondents’ general health and
OAB-related health which could be used in the modeling to
Table 1 OAB-5D classiﬁcation system
Urge
1. Not at all bothered by an uncomfortable urge to urinate
2. Bothered by an uncomfortable urge to urinate a little bit or somewhat
3. Bothered by an uncomfortable urge to urinate quite a bit
4. Bothered by an uncomfortable urge to urinate a great deal
5. Bothered by an uncomfortable urge to urinate a very great deal
Urineloss
1. Not at all bothered by urineloss associated with a strong desire to
urinate
2. Bothered by urineloss associated with a strong desire to urinate a little
bit or somewhat
3. Bothered by urineloss associated with a strong desire to urinate quite a
bit
4. Bothered by urineloss associated with a strong desire to urinate a great
deal
5. Bothered by urineloss associated with a strong desire to urinate a very
great deal
Sleep
1. Bladder symptoms interfered with your ability to get a good night’s rest
none of the time
2. Bladder symptoms interfered with your ability to get a good night’s rest a
little of the time
3. Bladder symptoms interfered with your ability to get a good night’s rest
some of the time
4. Bladder symptoms interfered with your ability to get a good night’s rest a
good bit or most of the time
5. Bladder symptoms interfered with your ability to get a good night’s rest
all of the time
Coping
1. Bladder symptoms caused you to plan “escape routes” to restrooms in
public places none of the time
2. Bladder symptoms caused you to plan “escape routes” to restrooms in
public places a little of the time
3. Bladder symptoms caused you to plan “escape routes” to restrooms in
public places some of the time
4. Bladder symptoms caused you to plan “escape routes” to restrooms in
public places a good bit or most of the time
5. Bladder symptoms caused you to plan “escape routes” to restrooms in
public places all of the time
Concern
1. Bladder symptoms caused you embarrassment none of the time
2. Bladder symptoms caused you embarrassment a little of the time
3. Bladder symptoms caused you embarrassment some of the time
4. Bladder symptoms caused you embarrassment a good bit or most of the
time
5. Bladder symptoms caused you embarrassment all of the time
OAB, overactive bladder.
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estimate the impact of respondents’ own health on their valua-
tion of other health states, and also familiarized the respondents
with the health state description of the OAB-5D.
The TTO technique was used for the valuation task. This asks
respondents to trade off between length of life and quality of life.
The TTO-prop method developed and used in the UK valuation
of EQ-5D by the Measurement and Valuation of Health (MVH)
project [16] was used in this survey. This has been shown to be
more reliable than a nonprops version [17].
Modeling Health State Values
The overall aim of modeling is to predict preference values for all
3125 health states deﬁned by the OAB-5D, based on the values
obtained on the selected 98 states and the “pits” state over the
valuation survey. The data from this type of valuation survey are
normally skewed and clustered by respondent. A number of
alternative models (taken from the study by Brazier et al.) [7] were
explored for predicting the TTO scores generated in the valuation
survey. The TTO scores were placed on a scale where 0 denotes
dead and 1 denotes full health. Respondents can value a health
state as being worse than dead, with a negative value as low as -1.
The general model is:
y g x r zij ij ij j ij= ′ + ′ + ′( ) +β θ δ ε
where: yij = TTO score for health state i valued by respondent j;
i = Individual health state values (1, 2, . . . , 99);
j = Individual respondents (1, 2, . . . , m);
g = Function specifying the appropriate functional
form;
x = A vector of binary dummy variables (xdl) for each
level l of dimension d of the classiﬁcation (level
l = 1 acts as the baseline for each dimension);
r = A vector of terms to account for interactions;
z = A vector of personal characteristics of respondents
(i.e., sex, age, etc.);
eij = Error term. Its autocorrelation structure and distri-
butional properties depend on the assumptions
underlying the particular model used.
Given the main purpose of this article is to provide a general
population value set for use in economic evaluation, the z term has
not been explored in this article.
Time-trade-off values can be negative (although bounded to
-1) if respondents value the health states under study as worse
than death. When estimating models, the transformed variable of
dis_TTO (1 - TTO) was used as dependent variable simply to
ensure the coefﬁcients are expected to have a more intuitive sign
(namely positive and larger with increasing severity). Given 1
denotes full health, the dependent variable dis_TTO indicates the
extent to which a given health state moves away from full health.
Thus, the more severe the ill health state, the greater the coefﬁ-
cient should be, and the expected signs of the dummy coefﬁcients
are positive.
The data were modeled at both an individual and an aggre-
gate level. The individual level model was a one-way error com-
ponents random effects model that takes account of variation
both within and between respondents, where the dependant vari-
able is the disvalue (dis_TTO) for health state i valued by respon-
dent j, with a vector of dummy explanatory variables deﬁned as
previously and an error term which is subdivided into a
respondent-speciﬁc variation and a random error term. Ordinary
least squares was used to estimate the aggregate model, where
mean health state values were the dependent variable and the
independent variables were a series of dummy explanatory vari-
ables representing each level of the ﬁve dimensions of the
OAB-5D. There are 20 of these terms in total with level 1 acting
as a baseline for each dimension.
OABq-5D full health 11111 was used as the upper anchor for
TTO method. Therefore, each model was estimated without a
constant term as dis_TTO was the dependent variable (this is
equivalent to forcing the constant equal 1). There is evidence that
preferences for different dimensions of health may not be addi-
tive [5,7]. Therefore, it is important to try to estimate interac-
tions. We did not consider analysis of ﬁrst-order interactions
because of the very large number of such coefﬁcients, and the
collinearity problem that may occur [7]. Adapting the approach
used in other studies (see, for example, the study by Brazier et al.)
[7], an interaction variable “N2_severe” was created as a dummy
variable which takes a value of 1 if two or more dimensions in
the health state are at level 4 or 5, and 0 if otherwise. The
creation of N2_severe was based on the assumption that possible
interactions would happen between severe levels of different
dimensions rather than between mild levels.
In addition, a series of empiric criteria were used to identify the
best model: Models were compared in terms of their adjusted
R-squared, the sign and signiﬁcance of individual parameter
estimates, the relative size of coefﬁcients within a given dimension
(in other words, logical consistency), as well as their predictive
ability measured by mean absolute error (MAE) and the numbers
of absolute errors greater than 0.05 and 0.10.
All analysis and modeling was carried out using SPSS 12.0 for
Windows (SPSS, Chicago, IL) and STATA 9.0 (StataCorp,
College Station, TX).
Results
Respondents
A random sample of the general population from South York-
shire in the UK was sent letters of invitation to take part in the
survey. The relevant numbers are reported in Table 2. The rate of
successful interviews to potential interview respondents is 27%,
although the rate of successful interviews to eligible respondents
is 52%. A total of 312 members of the public were successfully
interviewed, and their data are included in the subsequent analy-
sis. The description of the sample is shown in Table 3 in terms of
age, sex, education, general health, and position on the OAB-5D
dimension scale. This sample was shown to be representative of
the South Yorkshire general population in terms of age and sex.
Health State Values
Table 4 presents health state values for the 98 health states
valued in the survey, which formed the basis for modeling. In
Table 2 Recruitment information for the interview
Letters of invitation sent: 1440
Letters returned with vacant properties: 24
Refusals at this stage: 20
Properties called where resident were not at home: 415
Refusals when interviewer calls: 268
Respondents unsuitable for interview: 172
Other reasons for interview not going ahead: 179
Completed interviews: 312
Properties not visited: 61
Rate 1 = successful interviews/basic sample
= 312/1440 - (addressed vacant + not visited +
unsuitable respondents)
= 312/1440 - (24 + 61 + 172)
= 312/1183 = 27%
Rate 2 = successful interviews/total number of eligible respondents
= 312/(successful interviews + total number of respondents
refused to participate)
= 312/(312 + 20 + 268) = 52%
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total, there were 2487 health state values generated by the 311
respondents. Each intermediate health state was valued on
average 22 times (range from 17 to 29) and the worst possible
state (OAB-5D 55,555) was valued 310 times (one missing
value). Among the 2487 valuations, the proportion of health
states been given a value of 1 was 32% and the proportion of
health states been valued less than 0 was around 2%. Among the
310 valuations for the pits state, 13 valuations were valued as
less than 0 and 65 were given a value of 1. The mean health state
values ranged from 0.55 for state 32,435, to 0.91 for state
13,321, with an average standard deviation of 0.28. The stan-
dard deviations of states with lower TTO values tend to be larger
than those states with higher values. Figure 1 shows the distri-
bution of 2487 health state values to be negatively skewed, which
is the same as was found in other valuation studies (e.g., SF-6D
and EQ-5D).
The Main Models
The main results of modeling are presented in Table 5, with
summary statistics for internal sample predictions presented in
the lower part of the table. Model 1 was estimated at the indi-
vidual observation level although model 2 was estimated at the
aggregate level using mean health state values.
As expected, all the coefﬁcients are positive (in other words,
they increase with the TTO disvalue) and most were signiﬁcant.
The coefﬁcients are broadly consistent with the ordering of the
OAB-5D levels, so that a severer level within a dimension was
associated with a larger decrement. For example, the coefﬁcient
of level 5 in urge dimension (0.084 as urge5 in Table 5)
is greater than those of level 4 (0.068) and level 3 (0.031). There
were some inconsistencies between signiﬁcant coefﬁcients in each
model, but in all case except one were 0.01 or less. Examples
include urge2 and urge3, urine loss3 and urine loss4, and sleep4
and sleep5 in the random effect model (model 1) as well as urge4
and urge5, urine loss4 and urine loss5, and coping3 and coping4
in the mean model (model 2).
Compared to model 1, the mean model (model 2) had one
fewer inconsistency and performed better in terms of prediction
(MAE 0.044 vs. 0.075). Given that the main aim of modeling is
prediction, model 2 has been chosen as the better of the two. The
addition of the interaction terms N2_severe did not improve
either model so it was not included in the ﬁnal speciﬁcation of
either model.
To overcome the inconsistency problem identiﬁed with
model 2, we have merged those levels where the coefﬁcients are
inconsistent with the OAB-5D. The result is a “consistent”
model 3 that required the merging of 10 coefﬁcients to create
a model with 15 dummy variables (rather than 20 for the other
models). Model 3 has achieved consistency with little reduction
in the predictive performance (MAE moves from 0.044 to
0.045). This is the recommended model for use in economic
evaluation.
As the regression equation (Equation 1 below) shows, the
preference-based, OAB-speciﬁc single index (TTO) can be
explained by ﬁve dimensions in the OAB-5D classiﬁcation system
(urge, urine loss, sleep, coping, and concern) and each dimension
enters the equation as a set of dummy variables with health state
11111 acting as default. Therefore, for health state 11111, all
independent variables take a value of 0, which results in
preference-based index of 1.0. Taking another health state 12345
as example, dummies will enter Equation 1 and result in Equa-
tion 2. Using coefﬁcients of model 3, TTO value of health state
12345 will be calculated as 0.749. Note that in model 3, some
coefﬁcients have been merged so these merged levels have the
same coefﬁcients, such as urge3 and urge5, urine loss4 and urine
Table 3 Characteristics of respondents in valuation survey (N = 312)
Survey sample South Yorkshire*
Count Percentage Percentage
Age 18–25 37 11.9 N/A
26–35 57 18.3 18.5
36–45 61 19.6 19.7
46–55 51 16.4 17.3
56–65 45 14.5 14.5
>66 60 19.3 21.6
Female 160 51.4 51.2
Married or living with partner 217 69.8
Experienced serious illness
In family 176 56.6
Themselves 94 30.2
Degree or equivalent 85 27.3
Education after 17 182 58.5
Renting property 63 20.2
Found valuation task difﬁcult
Very difﬁcult 13 4.2
Quite difﬁcult 80 25.9
Neither difﬁcult nor easy 70 22.7
Self-reported OAB-5D health state Level 1 (%) Level 2 (%) Level 3 (%) Level 4 (%) Level 5 (%)
Urge 235 (75.8) 48 (15.5) 21 (6.8) 4 (1.3) 2 (0.6)
Urine loss 258 (83.2) 34 (11.0) 10 (3.2) 4 (1.3) 4 (1.3)
Sleep 206 (66.5) 62 (20.0) 25 (8.1) 14 (4.5) 3 (1.0)
Coping 242 (78.1) 40 (12.9) 17 (5.5) 8 (2.6) 3 (1.0)
Concern 264 (85.2) 33 (10.6) 9 (2.9) 2 (0.6) 2 (0.6)
Self-reported EQ-5D scores† Male Female
Respondent sample 0.88 0.88
UK population 0.86 0.85
*UK census 2001.
†Self-reported EQ-5D scores are based in the EQ-5D tariff of the York value and measure of health project.
N/A, not available; OAB, overactive bladder.
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Table 4 Description of TTO health state values
Health state N N* (%) Minimum Maximum Mean SD Median
32435 24 0.13 -0.35 1 0.55 0.35 0.5
55555 310 0.21 -0.88 1 0.56 0.39 0.63
34554 24 0.13 -0.25 1 0.59 0.32 0.57
31155 24 0.17 0 1 0.61 0.35 0.64
51454 24 0.21 -0.68 1 0.61 0.49 0.75
42554 21 0.14 0 1 0.62 0.32 0.68
54245 24 0.25 -0.88 1 0.63 0.43 0.74
42245 24 0.29 -0.88 1 0.66 0.44 0.82
23235 24 0.29 -0.73 1 0.66 0.51 0.85
53525 25 0.24 0.17 1 0.67 0.27 0.63
53325 25 0.16 0.17 1 0.67 0.24 0.7
34225 29 0.28 -0.57 1 0.67 0.39 0.82
43234 24 0.25 -0.43 1 0.67 0.46 0.88
23154 21 0.19 0.13 1 0.68 0.29 0.73
42214 24 0.25 -0.47 1 0.68 0.47 0.86
33245 28 0.25 -0.47 1 0.69 0.38 0.77
11445 28 0.29 -0.63 1 0.69 0.39 0.79
14444 21 0.14 0.32 1 0.7 0.24 0.7
42542 24 0.21 0.03 1 0.7 0.28 0.74
24422 24 0.25 0.03 1 0.7 0.3 0.77
54152 21 0.19 0.03 1 0.7 0.28 0.77
15553 28 0.29 -0.68 1 0.7 0.37 0.82
54333 24 0.29 -0.63 1 0.7 0.44 0.89
23534 25 0.16 0.08 1 0.71 0.26 0.8
45532 20 0.35 0.03 1 0.71 0.32 0.83
32235 24 0.38 -0.88 1 0.71 0.44 0.88
13434 23 0.17 0.28 1 0.72 0.24 0.77
35453 23 0.22 0.22 1 0.72 0.27 0.77
51214 20 0.30 0.03 1 0.72 0.36 0.93
24524 23 0.26 0.28 1 0.73 0.24 0.77
24335 20 0.30 0 1 0.73 0.29 0.81
31531 24 0.17 0.03 1 0.73 0.3 0.86
42325 24 0.38 -0.88 1 0.73 0.47 0.93
41125 25 0.20 0.08 1 0.74 0.24 0.8
44114 21 0.29 0 1 0.74 0.3 0.9
33323 21 0.14 0.22 1 0.75 0.24 0.88
25425 22 0.36 0.08 1 0.75 0.29 0.93
31215 27 0.30 -0.68 1 0.75 0.37 0.93
34254 20 0.35 0 1 0.75 0.32 0.93
54123 20 0.30 0.03 1 0.76 0.27 0.83
45253 21 0.29 0.03 1 0.76 0.28 0.93
55521 23 0.22 0.3 1 0.77 0.2 0.77
25313 24 0.38 -0.88 1 0.77 0.39 0.86
15131 23 0.30 0.03 1 0.77 0.3 0.93
44135 20 0.50 0.17 1 0.77 0.3 0.96
33132 24 0.50 -0.4 1 0.77 0.45 1
52444 20 0.35 0.25 1 0.78 0.24 0.85
41153 25 0.28 0.08 1 0.78 0.25 0.88
55424 17 0.29 0 1 0.78 0.27 0.88
34351 20 0.40 0.03 1 0.78 0.3 0.93
35422 21 0.33 0 1 0.79 0.3 0.93
45143 21 0.38 0.03 1 0.79 0.28 0.93
53242 20 0.50 0.17 1 0.79 0.29 0.96
13514 20 0.30 0.32 1 0.8 0.21 0.81
14341 21 0.29 0.15 1 0.8 0.23 0.88
13431 25 0.28 0.08 1 0.8 0.25 0.9
32414 29 0.34 0 1 0.8 0.27 0.93
45553 21 0.33 0.13 1 0.8 0.27 0.93
53411 20 0.45 0.22 1 0.81 0.24 0.89
15355 22 0.41 0.08 1 0.81 0.28 0.93
52141 23 0.35 0.3 1 0.81 0.22 0.93
41322 24 0.50 -0.77 1 0.81 0.38 0.99
41123 23 0.39 0.3 1 0.82 0.22 0.93
53532 21 0.38 0.03 1 0.82 0.29 0.95
12511 28 0.36 -0.68 1 0.82 0.35 0.96
32412 20 0.50 0.13 1 0.82 0.28 0.96
12314 19 0.47 0.03 1 0.82 0.29 0.99
25543 20 0.50 0.08 1 0.82 0.28 1
25421 20 0.45 0.13 1 0.83 0.24 0.91
13251 22 0.41 0.08 1 0.83 0.25 0.93
15251 22 0.41 0.08 1 0.83 0.25 0.93
32441 21 0.29 0.43 1 0.83 0.2 0.93
52314 18 0.44 0.43 1 0.83 0.23 0.93
14225 21 0.43 0.03 1 0.83 0.25 0.95
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loss5. An SPSS syntax ﬁle is available from the correspondence
on request which can be used to calculate OAB-speciﬁc utility
values on the basis of the OAB-q.
TTO urge urine loss sleep coping concern= − + + +( + )1 (1)
TTO
TTO urge urine loss sleep
_
_
11111 1 0 0 0 0 0
12345 1 1 2
= − + + + +( )
= − + + 3
4 5
1 0 0 026 0 023 0 060 0 142
0 749
+(
+ )
= − + + + +( )
=
coping concern
. . . .
. (2)
Table 4 Continued
Health state N N* (%) Minimum Maximum Mean SD Median
12543 20 0.50 0.13 1 0.83 0.26 0.96
21113 25 0.40 0.08 1 0.84 0.23 0.93
24133 20 0.40 0.03 1 0.84 0.24 0.93
41442 22 0.36 0.35 1 0.84 0.21 0.93
51451 22 0.45 0.13 1 0.85 0.26 0.99
25112 25 0.36 -0.4 1 0.85 0.3 1
41112 20 0.55 0.13 1 0.85 0.25 1
11233 21 0.33 0.38 1 0.86 0.18 0.93
21332 20 0.25 0.47 1 0.86 0.18 0.93
24433 21 0.33 0.32 1 0.86 0.21 0.93
31143 20 0.50 0.22 1 0.86 0.21 0.97
45341 20 0.45 0.32 1 0.86 0.21 0.97
15331 23 0.35 0.3 1 0.87 0.17 0.93
22242 21 0.38 0.47 1 0.87 0.17 0.95
12144 21 0.43 0.17 1 0.87 0.24 1
24352 18 0.50 0.22 1 0.87 0.24 1
41211 22 0.45 0.08 1 0.88 0.23 0.95
21223 21 0.52 0.17 1 0.88 0.22 1
33552 18 0.50 0.32 1 0.88 0.2 1
51522 21 0.38 0.47 1 0.88 0.16 1
15311 25 0.40 0.38 1 0.89 0.16 0.95
52112 18 0.56 0.2 1 0.89 0.22 1
23312 19 0.53 0.47 1 0.9 0.16 1
13321 20 0.55 0.17 1 0.91 0.2 1
33511 18 0.50 0.5 1 0.91 0.14 1
The table is ranked by means of health state values.
Health state: OAB-5D health states been valued using TTO technique.
N:Times of health state been valued.
N*: Percentage of times a health state was given a value of 1 which is equivalent to perfect health.
OAB, overactive bladder;TTO, time-trade-off.
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Figure 1 Distribution of health state values using
TTO.TTOC are OAB-5D health state values based
on TTO technique. OAB, overactive bladder;TTO,
time-trade-off.
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Discussion and Conclusion
The methodology used in this study was the same as that used to
estimate the SF-6D population value set from the generic SF-36.
The study reported in this article is one of a number that have
shown it is possible to estimate a preference-based measure for a
condition-speciﬁc measure [18–20]). The models of the health
state valuation data were broadly consistent with the descriptive
system and achieved levels of predictive performance as good as
or better than those for generic health state descriptive systems,
such as the EQ-5D and SF-6D [5,7].
The OAB-5D-described health states would probably be
regarded as mild compared to the EQ-5D or SF-6D and this is
reﬂected in the ranges of scores, starting from 0.56 for the worst
OAB-5D state compared to 0.21 for the SF-6D and negative
values for the EQ-5D and HUI3. For sufferers of OAB, it is a
bothersome condition that impacts signiﬁcantly on their health-
related quality of life but it is not as debilitating as some other
physical and mental disorders. There have been similar ﬁndings
for other preference-based measures using descriptions for milder
conditions, with the Kings Health Questionnaire for urinary
incontinence having a lowest value of 0.77 [18] and the Interna-
tional Index of Erectile Dysfunction a lowest value of 0.73 [21].
The original interest in developing a condition-speciﬁc
preference-based measure rather than using an existing generic
measure was that the latter may be insensitive to important
differences or indeed may miss important dimensions altogether
[22,23]. Nevertheless, there is a concern that condition-speciﬁc
preference-based measures will not achieve comparability with
other preference-based measures and so can only be used to
inform resource allocation within a condition [24]. We have
argued elsewhere that the problem of comparability can be partly
overcome by: 1) using the same valuation protocol; 2) ensuring
common upper and lower anchors; and 3) obtaining values from
the same population [8].
We have used the same variant of the TTO as the UK EQ-5D
valuation study (the MVH project) on a general population, and
the upper anchor of state 11,111 deﬁned by the OAB-5D is
arguably similar to state 11111 of the EQ-5D. Differences
between the scores produced by the OAB-5D and the EQ-5D
should be solely due to differences in the descriptive system. An
important rider to this claim, however, is that the upper anchors
are not strictly the same, and it assumes that the values given to
the dimensions of this instrument are independent of dimensions
excluded from OAB-5D. Because we did not cover other dimen-
sions of health in the valuation survey, we do not know what a
respondent was considering besides urinary issues when pre-
sented with OAB-5D health states. Thus, the values given to the
OAB-speciﬁc dimensions may not be independent of whether or
not a person has comorbidities that result in other health prob-
lems like pain. The extent of this problem needs to be explored
further in the future.
This article reports on a study that enables the derivation
of preference-based single indices from the condition-speciﬁc
quality of life instrument, OAB-q. Researchers with OAB-q
patient data can allocate an OAB-5D health state to each OAB-q
observation and use the coefﬁcients in the consistent model 3 to
predict a preference-based index for use in economic evaluation.
Given ﬁndings of differences between the EQ-5D scores across
countries (see for example the studies by Tsuchiya et al. and
Johnson et al.) [25,26], researchers outside the UK need to use
the scoring system presented here with caution, as it is based on
the UK general public’s preference. Another concern is the rel-
evance of the wording of some items across different cultures. For
instance, the “coping” dimension refers to “the restroom” (US/
North American terminology taken from the original instru-
ment), whereas the valuation is based on a South Yorkshire UK
population, not all of whom may relate to this. The OAB-5D
classiﬁcation system was established by taking ﬁve items from the
original instrument directly without any change, and cultural
adaptation was not pursued, to maintain the maximum link
between the two instruments. Nevertheless, feedback from the
interviewers suggests that this phrase did not cause any difﬁcul-
ties among the respondents.
The results in this article may contribute toward extending
the application of cost per QALY analysis in OAB. The three-
stage approach explored in this study offers a feasible approach
to estimating disease-speciﬁc utilities where there is a validated
nonpreference-based HRQoL instrument. Nevertheless, there
remains further scope for explore, such as to what is the effect
of naming the speciﬁc condition on health states valuation, and
how to deal with comorbidities and side effects which are not
incorporated in a condition-speciﬁc descriptive system. Further
research is needed to address these issues and make general
claims on this approach.
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Table 5 Estimated models
Dimension levels
Complete models
Mean model with
merged levels
RE (1) Mean (2) Mean (3)
Urge2 0.034 0.034 0.036
Urge3 0.031 0.068 0.070
Urge4 0.068 0.081 0.078
Urge5 0.084 0.076 —
Urineloss2 0.020 0.032 0.026
Urineloss3 0.049 0.036 0.038
Urineloss4 0.031 0.047 0.045
Urineloss5 0.047 0.044 —
Sleep2 0.028 0.028 0.023
Sleep3 0.019 0.020 —
Sleep4 0.056 0.049 0.049
Sleep5 0.052 0.050 —
Coping2 0.008 0.032 0.030
Coping3 0.021 0.073 0.060
Coping4 0.022 0.046 —
Coping5 0.066 0.081 0.080
Concern2 0.033 0.022 0.022
Concern3 0.045 0.047 0.048
Concern4 0.088 0.110 0.113
Concern5 0.136 0.139 0.142
N 2487 99 99
Adj. R2 N/A N/A
Inconsistencies 4 3 0
Signiﬁcant coefﬁcients 14 13 10
Mean absolute error 0.076 0.044 0.045
No. > |0.05| 57 39 40
No. > |0.10| 27 8 6
Independent variable: dis_TTO = 1 - TTO.
Mean absolute error: mean of difference between observed and predicted values.
No. > |0.05|: number of observations with absolute difference between observed and pre-
dicted values greater than 0.05.
No. > |0.10|: number of observations with absolute difference between observed and pre-
dicted values greater than 0.10.
Estimates showed in bold are signiﬁcant at the 0.05 level.
Inconsistencies: count for signiﬁcant coefﬁcients.
N/A, not available;TTO, time-trade-off.
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